

The Stock Exchange of Hong Kong Limited takes no responsibility for the contents of this announcement, makes no representation as to its accuracy or completeness and expressly disclaims any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CK Life Sciences Int'l. (Holdings) Inc.

長 江 生 命 科 技 集 團 有 限 公 司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 8222)

RE-DESIGNATION OF DIRECTOR

The Board of Directors (the “Board”) of CK Life Sciences Int’l. (Holdings) Inc. (the “Company”) announces that effective from 23rd September, 2004, Mr. Kwan Chiu Yin, Robert, a Non-executive Director of the Company, has been re-designated as an Independent Non-executive Director of the Company.

Mr. Kwan Chiu Yin, Robert, JP, aged 67, is a retired Certified Public Accountant. Mr. Kwan received his Master of Arts degree at Cambridge University and qualified as a Fellow of the Institute of Chartered Accountants in England and Wales and a Fellow of the Hong Kong Institute of Certified Public Accountants. He was the Past Chairman of Deloitte Touche Tohmatsu, Certified Public Accountants in Hong Kong and Ocean Park Corporation and is currently an Independent Non-executive Director of Cheung Kong (Holdings) Limited, Pak Fah Yeow International Limited, Melco International Development Limited and Shun Tak Holdings Limited. Mr. Kwan does not have any relationship with any other Directors, senior management, management shareholders, substantial shareholders or controlling shareholders of the Company. He has a corporate interest of 500,000 shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance. There is no service contract entered into between Mr. Kwan and the Company. Pursuant to the Company’s Articles of Association, Mr. Kwan is subject to retirement by rotation and will be eligible for re-election at annual general meetings of the Company. Mr. Kwan will receive a Director’s fee of HK\$70,000 per annum and a further fee of HK\$70,000 per annum for being a member of the Audit Committee of the Company. Such fees are subject to review by the Board from time to time pursuant to the power given to it under the Articles of Association of the Company.

Mr. Kwan was originally appointed as an Independent Non-executive Director of the Company on 1st June, 2002 and was designated as a Non-executive Director of the Company on 26th June, 2002 due to the “cooling-off” period criteria proposed to be introduced to the independence qualification at the relevant time. Since such “cooling-off” period criteria have now been complied with, the Company is of the view that Mr. Kwan meets the independence requirements of the Rules Governing the Listing of Securities on the Growth Enterprise Market of The Stock Exchange of Hong Kong Limited.

Save as disclosed herein, there are no other matters relating to the above re-designation of Director that need to be brought to the attention of the shareholders of the Company.

By Order of the Board
CK Life Sciences Int'l, (Holdings) Inc.
Eirene Yeung
Company Secretary

Hong Kong, 23rd September, 2004

As at the date of this announcement, the Executive Directors of the Company are Mr. Li Tzar Kuoi, Victor (Chairman), Mr. Kam Hing Lam, Mr. Ip Tak Chuen, Edmond, Mr. Yu Ying Choi, Alan Abel, Dr. Pang Shiu Fun, Dr. Chu Kee Hung and Mr. Lam Hing Chau, Leon; and the Non-executive Directors are Mr. Kwan Chiu Yin, Robert (Independent Non-executive Director), Mr. Peter Peace Tulloch, Professor Wong Yue-chim, Richard (Independent Non-executive Director) and Mrs. Kwok Eva Lee (Independent Non-executive Director).

This announcement, for which the Directors of the Company collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on the Growth Enterprise Market of The Stock Exchange of Hong Kong Limited for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief: (i) the information contained in this announcement is accurate and complete in all material respects and not misleading; (ii) there are no other matters the omission of which would make any statement in this announcement misleading; and (iii) all opinions expressed in this announcement have been arrived at after due and careful consideration and are founded on bases and assumptions that are fair and reasonable.

This announcement will remain on the "Latest Company Announcements" page of the GEM website at www.hkgem.com for at least 7 days from the date of its posting and on the website of the Company at www.ck-lifesciences.com.